The use of serotonin reuptake inhibitors increases the risk of bleeding in patients with assist devices

• DOI: 10.1186/s12872-022-02557-1
• Publication Date: 2022-03-22T10:03:35Z
• Authors: Bianca Auschra; Markus J. Wilhelm; Claudia Husung; Josef Jenewein; Andreas J. Flammer; Lena Jellestad
• Keywords: Serotonin reuptake inhibitors; 610 Medicine & health; Heart failure; Hemorrhage; 2705 Cardiology and Cardiovascular Medicine; 03 medical and health sciences; 0302 clinical medicine; Diseases of the circulatory (Cardiovascular) system; Humans; Retrospective Studies; Heart Failure; Bleeding; Antidepressants; 10020 Clinic for Cardiac Surgery; 3. Good health; 10057 Klinik für Konsiliarpsychiatrie und Psychosomatik; Treatment Outcome; RC666-701; 10209 Clinic for Cardiology; Ventricular assist device; Heart-Assist Devices; Cardiology and Cardiovascular Medicine; Selective Serotonin Reuptake Inhibitors; Research Article

Abstract Background Bleedings are frequent and dreaded complications in heart failure patients with ventricular assist devices (VAD). Serotonin reuptake inhibitor (SRI) antidepressants are widely used to treat depression in these patients, though they are attributed an increased risk of bleeding due to their modification of hemostasis. Evidence on bleeding risk of VAD patients under SRI medication is scarce and limited. We therefore aimed to assess if SRI use is associated with an elevated bleeding risk in this particularly vulnerable population.

Methods We analyzed the medical records of 92 VAD patients at the University Heart Center Zurich between September 2004 and April 2018 for the occurrence of bleedings and the concomitant use of an SRI. Bleeding was defined as any type of post-implantation bleeding requiring medical treatment. We performed univariate analyses and linear mixed-effects models, adjusting for baseline clinical characteristics as potential predictors to identify differences in bleeding rates in patients with vs. without SRI intake.

Results The cohort comprised 60.9% of patients with a continuous-flow VAD and 39.1% with a pulsatile-flow VAD. A total of 77.2% of patients experienced at least one bleeding incident. Overall, 28.6% of bleedings occurred under SRI therapy. A generalized linear mixed model showed a predictive effect of SRI medication on bleeding rate, independent of VAD type (z = 2.091, p = 0.037).

Conclusions Bleeding events in heart failure patients occur frequently after VAD implantation. Patients with SRI medication were at increased risk of bleeding. The indication and use of SRI, therefore, should be considered carefully.